2024-12-18 JPX Market Innovation & Research, Inc. HaiPress
TOKYO,Dec. 12,2024 -- The JPX Market Innovation & Research,Inc.,a group company of Japan Exchange Group,Inc. (JPX),began provision of "JPxData Portal (beta version)" (hereinafter referred to as "the Portal"),a data portal to browse the over 200 data types provided by JPX and partner companies including basic information and disclosure materials from Tokyo Stock Exchange (TSE) listed companies as well as search by characteristic and usage method,as of August 2024.
Update Contents
We have implemented the following updates to the Portal:
- Addition of indicators for analysis (including stock price,market capitalization,earnings) to the details page of each company's issue profile.
For detailed usage information,please click on the following link.
JPxData Portal (beta version) "Tutorial: How to Use Company Search"
(https://clientportal.jpx.co.jp/ClientPortalEN/s/recipe2024040504)
Learn More about"JPxData Portal (beta version)"
For JPxData Portal (beta version) website,please click on the following link.
JPxData Portal (beta version) : https://clientportal.jpx.co.jp/ClientPortalEN/s/
Future update plans
We are continuing to consider development of the following additional features:
- Login function and additional features for logged-in users
- Procedural functions related to contracts
- Simple data analysis functions
- Collaboration with external partners
About JPX Market Innovation & Research
JPX Market Innovation & Research,Inc. (JPXI) was established as a subsidiary of Japan Exchange Group,Inc. (TOKYO:8697)in 2022. It consolidates JPX Group's data/index services and system-related services,and leads further business enhancement of JPX Group by leveraging IT technologies and new business partnerships.
Contact
Frontier Development Department,
JPX Market Innovation & Research,Inc.
E-mail: inf_dev@jpx.co.jp
Inquiry form: https://clientportal.jpx.co.jp/ClientPortalEN/s/InquiryFormEn
Cangxi County Holds 2026 New Year's Cultural Performance for the Public
The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully
The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully
Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange
Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference
Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement
©copyright 2009-2020 Diet Tips Daily